Lupin settles ongoing litigation with Medicis

26 Jul 2011 Evaluate

Lupin and its subsidiary, Lupin Pharmaceuticals, Inc have settled all ongoing litigation over Solodyn (minocycline HCI, USP) extended release tablets with Medicis Pharmaceutical Corporation.

The settlement entitles Lupin to sell its generic versions of Solodyn in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011 or earlier under certain conditions. The settlement also entitles Lupin to sell its generic versions of Solodyn in 65mg and 115mg strengths under a license from Medicis effective in February 2018 or earlier under certain conditions.

In addition, the settlement entitles Lupin to sell its generic versions of Solodyn in 55mg, 80mg and 105mg strengths under a license from Medicis effective in February 2019 or earlier under certain conditions.

Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.